Tenaya Therapeutics, Inc. (TNYA)
| Market Cap | 169.91M +104.9% |
| Revenue (ttm) | 225,000 |
| Net Income | -83.01M |
| EPS | -0.47 |
| Shares Out | 217.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,327,268 |
| Open | 0.8366 |
| Previous Close | 0.8573 |
| Day's Range | 0.7600 - 0.8600 |
| 52-Week Range | 0.3901 - 2.3500 |
| Beta | 2.77 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+410.86%) |
| Earnings Date | May 6, 2026 |
About TNYA
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for TNYA stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 410.86% from the latest price.
News
Tenaya Therapeutics Transcript: Study update
Interim results from the RIDGE-1 trial show TN-401 gene therapy for PKP2-associated ARVC led to consistent, durable reductions in arrhythmia burden and was well tolerated at both tested doses. Biopsy data confirmed robust gene delivery and expression, supporting TN-401’s disease-modifying potential.
Tenaya reports data from RIDGE-1 Phase 1b/2 clinical trial of TN-401
Tenaya Therapeutics (TNYA) presented interim data from the ongoing RIDGE-1 Phase 1b/2 clinical trial of TN-401 gene therapy at the American Society of Gene and Cell Therapies, or ASGCT, 2026…
Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies P...
Tenaya Therapeutics reports Q1 EPS (9c), consensus (9c)
Reports Q1 revenue $225,000, consensus $7.5M. “We are entering a catalyst-rich period for Tenaya, with multiple clinical milestones expected across our lead gene therapy programs throughout 2026. Buil...
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2 ...
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
SOUTH SAN FRANCISCO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potenti...
Tenaya Therapeutics Duchenne muscular dystrophy treatment granted orphan status
Tenaya Therapeutics (TNYA)’ treatment of Duchenne muscular dystrophy was granted FDA orphan designation status, according to a post to the agency’s website.
Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)
“As we enter 2026, we are energized by the momentum and clinical advances achieved over the past year,” said Faraz Ali, CEO of Tenaya. “The encouraging data presented in 2025…
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026
Tenaya Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Three clinical-stage programs are advancing efficiently, with TN-301 showing broad preclinical efficacy and TN-201 and TN-401 progressing in gene therapy trials. The Alnylam partnership adds significant capital and pipeline depth, while upcoming data and regulatory milestones are expected to drive further value.
Tenaya Therapeutics presents preclinical data evaluating TN-301
Tenaya Therapeutics (TNYA) presented preclinical data evaluating TN-301, the company’s highly selective HDAC6 inhibitor, at the Muscular Dystrophy Association’s Clinical & Scientific Conference 2026. ...
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
Tenaya's Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments
Tenaya Therapeutics said on Thursday it has signed a research deal with Alnylam Pharmaceuticals worth up to $1.13 billion to develop treatments for heart diseases.
Tenaya Therapeutics enters research collaboration with Alnylam
Tenaya Therapeutics (TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (ALNY) to discover novel human genetic targets for the potential development of disease-modifying t...
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
Agreement Combines Tenaya's Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam's Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Mill...
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potenti...
Tenaya Therapeutics announces 2026 strategic priorities
Tenaya Therapeutics (TNYA) provided an update on its clinical development programs and outlined its strategic priorities for 2026. “2025 was a momentous year for Tenaya as we demonstrated early eviden...
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM
Tenaya Therapeutics price target lowered to $2 from $5 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $2 from $5 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S.
Tenaya Therapeutics price target lowered to $4 from $6 at Canaccord
Canaccord lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $4 from $6 and keeps a Buy rating on the shares. The firm two key updates from the company;…
Tenaya Therapeutics price target lowered to $3 from $5 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $3 from $5 and keeps a Buy rating on the shares. The firm cites dilution from the equity…
Tenaya Therapeutics price target lowered to $8 from $9 at Chardan
Chardan analyst Geulah Livshits lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $8 from $9 and keeps a Buy rating on the shares after the company announced data…
Tenaya Therapeutics 50M share Spot Secondary priced at $1.20
Leerink and Piper Sandler acted as joint book running managers for the offering.
Tenaya Therapeutics Announces Pricing of Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia...
Tenaya Therapeutics Transcript: Study Result
Initial results from the RIDGE-1 trial show TN-401 gene therapy is well tolerated and demonstrates robust molecular and early clinical efficacy in PKP2-associated ARVC, with significant reductions in arrhythmia burden and increased PKP2 protein levels. Data compare favorably to peers and support further development.